{
    "clinical_study": {
        "@rank": "110983", 
        "arm_group": [
            {
                "arm_group_label": "Xenon  and propofol", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "propofol", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators hypothesize that the application of 30% xenon as an adjuvant to general\n      anesthesia with a target-controlled infusion of propofol is superior to general anesthesia\n      with propofol alone with respect to hemodynamic stability."
        }, 
        "brief_title": "Xenon as an Adjuvant to Propofol Anaesthesia in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery.", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Anesthesia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with coronary artery disease scheduled for elective OPCAB-surgery\n\n          -  patients willing and able to complete the requirements of this study\n\n          -  Ejection fraction >30%\n\n        Exclusion Criteria:\n\n          -  Lack of informed consent\n\n          -  age < 18 years\n\n          -  COPD GOLD >II\n\n          -  Renal dysfunction defined as serum-creatinine >1.5mg/dl\n\n          -  acute coronary syndrome during the last 24 hours; haemodynamic    instability,\n             requirement of inotropic support\n\n          -  single vessel grafting\n\n          -  disabling neuropsychiatric disorders (severe dementia, Alzheimer's disease,\n             schizophrenia, depression, low preoperative cognitive state (MMSE at baseline <25),\n             history of stroke with residuals, increased intracranial pressure\n\n          -  Hypersensitivity to the study medication\n\n          -  Presumed uncooperativeness or legal incapacity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948765", 
            "org_study_id": "SR022013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Xenon  and propofol", 
                "description": "xenon 30% in oxygen as an adjuvant to propofol target  controlled infusion (target of 0.5-1.5\u00b5g/ml)", 
                "intervention_name": "Xenon and propofol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "propofol", 
                "description": "propofol target controlled infusion (target 1.5-2.5\u00b5g/ml)", 
                "intervention_name": "propofol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Propofol", 
                "Xenon"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "xenon anesthesia", 
            "Off-pump coronary artery bypass graft surgery"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium", 
                    "zip": "3000"
                }, 
                "name": "University Hospitals Leuven"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "Xenon as an Adjuvant to Propofol Anaesthesia in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery:a Randomised Controlled Trial", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Belgium:  Federal Agency for Medicinal & Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Haemodynamic stability as assessed by the individual intraoperative noradrenaline consumption", 
            "measure": "intraoperative haemodynamic stability", 
            "safety_issue": "Yes", 
            "time_frame": "intra-operative"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948765"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universitaire Ziekenhuizen Leuven", 
            "investigator_full_name": "prof Dr Steffen Rex", 
            "investigator_title": "PhD, MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Death from any cause, perioperative life-threatening cardiac arrhythmias, perioperative myocardial infarction, requirement of surgical revisions at the coronary vessels, postoperative coronary angioplasty and stroke", 
                "measure": "MACCE (major adverse cardiac and cerebral events)", 
                "safety_issue": "Yes", 
                "time_frame": "up to six months postoperative"
            }, 
            {
                "description": "cerebrovascular accident not included in MACCE (TIA, reversible ischaemic neurologic deficit)", 
                "measure": "cerebrovascular accident not included in MACCE", 
                "safety_issue": "Yes", 
                "time_frame": "up to six months postoperative"
            }, 
            {
                "description": "postoperative renal function as assessed by serum creatinine and BUN levels)", 
                "measure": "postoperative renal function", 
                "safety_issue": "Yes", 
                "time_frame": "up to five days postoperative"
            }, 
            {
                "description": "requirement for blood(product) transfusion", 
                "measure": "requirement for blood(product) transfusion", 
                "safety_issue": "Yes", 
                "time_frame": "up to five days postoperative"
            }, 
            {
                "description": "requirement for blood(product) transfusion", 
                "measure": "length of stay", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 10 days."
            }, 
            {
                "description": "Severity of postoperative critical illness as indicated by the new simplified acute physiology score (SAPS II), SOFA and APACHE-II score", 
                "measure": "severity of postoperative critical illness", 
                "safety_issue": "Yes", 
                "time_frame": "up to five days postoperative"
            }, 
            {
                "description": "incidence and duration of postoperative delirium assessed with the Confusion Assessment Method (CAM-ICU), to be assessed in combination with the Mini Mental State Examination", 
                "measure": "incidence and duration of postoperative delirium", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expectged average of 10 days"
            }, 
            {
                "measure": "incidence of further AE, SAE and SUSAR", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 10 days"
            }
        ], 
        "source": "Universitaire Ziekenhuizen Leuven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}